The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial

Scagliotti, 2013, Current state-of-the-art therapy for advanced squamous cell lung cancer, 354 Iyer, 2014, The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study, Support Care Cancer, 22, 181, 10.1007/s00520-013-1959-4 Siegel, 2014, Cancer statistics, 2014, CA Cancer J Clin, 64, 9, 10.3322/caac.21208 Janssen-Heijnen, 1998, Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study, Lung Cancer, 21, 105, 10.1016/S0169-5002(98)00039-7 Janssen-Heijnen, 2004, Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer, Thorax, 59, 602, 10.1136/thx.2003.018044 Putila, 2014, Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer, PLoS One, 9, e100994, 10.1371/journal.pone.0100994 Rubin, 2009 Ellis, 2014, American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes, J Clin Oncol, 32, 1277, 10.1200/JCO.2013.53.8009 Oliver, 2015, Squamous non–small cell lung cancer as a distinct clinical entity, Am J Clin Oncol, 38, 220, 10.1097/COC.0b013e3182a0e850 Perez-Moreno, 2012, Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities, Clin Cancer Res, 18, 2443, 10.1158/1078-0432.CCR-11-2370 Al-Farsi, 2014, Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line, Front Oncol, 4, 157, 10.3389/fonc.2014.00157 National Comprehensive Cancer Network NNCC. NCCN clinical practice guidelines in oncology—non-small cell lung cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed October 28, 2015. Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375 Socinski, 2012, Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial, J Clin Oncol, 30, 2055, 10.1200/JCO.2011.39.5848 Socinski, 2013, Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer, Ann Oncol, 24, 2390, 10.1093/annonc/mdt235 Sandler, 2010, Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer, J Thorac Oncol, 5, 1416, 10.1097/JTO.0b013e3181da36f4 Cetin, 2011, Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program, Clin Epidemiol, 3, 139, 10.2147/CLEP.S17191 Thatcher, 2015, Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial, Lancet Oncol, 16, 763, 10.1016/S1470-2045(15)00021-2 Hollen, 1994, Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale, Cancer, 73, 2087, 10.1002/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-X Nord, 1991, EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway, Health Policy, 18, 25, 10.1016/0168-8510(91)90141-J EQ-5D. Home page. http://www.euroqol.org/home.html. Accessed October 28, 2015. de Marinis, 2008, Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer, J Thorac Oncol, 3, 30, 10.1097/JTO.0b013e31815e8b48 Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clinic Proc. Elsevier; 2002;77:371–383. Norman, 2003, Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation, Med Care, 41, 582, 10.1097/01.MLR.0000062554.74615.4C Cox, 1972, Regression models and life-tables, J Royal Stat Soc Ser B, 34, 187 Reck, 2015, Maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the Phase III SQUIRE study, J Clin Oncol, 33, 8099, 10.1200/jco.2015.33.15_suppl.8099 Cella, 2004, Quality of life considerations in patients with advanced lung cancer, Semin Oncol, 31, 16, 10.1053/j.seminoncol.2004.10.004 Little, 2007, National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care, Lung Cancer, 57, 253, 10.1016/j.lungcan.2007.03.012 Pirker, 2013, EGFR-directed monoclonal antibodies in non-small cell lung cancer, Target Oncol, 8, 47, 10.1007/s11523-012-0244-7 Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9 Ray, 2009, The role of EGFR inhibition in the treatment of non-small cell lung cancer, Oncologist, 14, 1116, 10.1634/theoncologist.2009-0054 Chen, 2013, Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: a meta-analysis, Oncol Lett, 5, 1915, 10.3892/ol.2013.1301